Biology Reference
In-Depth Information
Table 3.1
Currently Known Hematopoietic mHags and their Therapeutic Potential
Estimated
Disparity in MUD
Setting (%)
Immunogenic
Peptide
mHag
Frequency
*
HLA
Restriction
HLA
Frequency
†
Tissue
Distribution
Malignant Cell
Expression
Reference
Number
mHag
HA-1
VL
H
DDLLEA
58,8
A*0201/*06
47,0
Hematopoietic
Myeloid, lymphoid, solid
tumors
11,3
25,78
B*60
9,6
2,3
29
HA-2
YIGEVLVS
V
94,5
A*0201
47,0
Hematopoietic
Myeloid, lymphoid
tumors
2,4
24
HB-1
EEKRGSL
H
VW 94,8
B*4402/03
9,5
B-ALL specific
B-ALL
1,3
28
EEKRGSL
Y
VW
46,3
6,8
28
ACC1
DYLQ
Y
VLQI
46,5
A*2402
15,5
Hematopoietic
Myeloid,
lymphoid,
solid tumors
3,9
32
DYLQ
C
VLQI
93,0
9,5
1,0
41
ACC2
KEFEDDIINW
44,5
B*4403
2,3
32
ACC6
MEIFIEVFSHF
33,0
B*4402/03
9,5
Myeloid, lymphoid
tumors
2,1
48
LRH-1
TP
NQRQNVC
54,0
B*0702
25,7
Hematopoietic
Myeloid,lymphoid,
solid tumors
6,4
36
PANE-1
RVWDLPGVLK
92,6
A*0301
26,3
B-cell
specific
B-CLL
1,8
37
SP110
SLP
R
GTSTPK
85,3
A*0301
26,3
Hematopoietic
Myeloid, lymphoid
tumors
3,3
38
HEATR1
ISKERA
E
AL
55,0
B*0801
22,5
Hematopoietic
Myeloid, lymphoid
tumors
5,6
43
UTA2-1
QL
L
NSVLTL
40,2
A*0201
47,0
Hematopoietic
Lymphoid, myeloid
tumors
11,3
submitted
CD19
L
WEGEPPC
L
P
53,4
DQA1*0502/
B1*0201
33,9
B-cell
specific
B-cell tumors (except
MM)
11,2
39
LB-LY75-1K
GITYRN
K
SLM
39,7
DRB1*13
8,8
Hematopoietic
Lymphoid, myeloid
tumors
2,1
42
Bold and underlined sequences indicate the differences from the allelic counterpart.
*Frequency data derived from Hap
‐
Map databases or from the original reference.
†
Frequency data derived from www.allelefrequencies.net
Search WWH ::
Custom Search